Featured Research

from universities, journals, and other organizations

UNC Researchers Testing First In New Class Of AIDS Drugs

Date:
January 29, 1999
Source:
University Of North Carolina At Chapel Hill
Summary:
AIDS investigators at the University of North Carolina at Chapel Hill are testing the first of a new class of drugs that attacks HIV before it enters the cell and may prove effective for patients with drug-resistant HIV.

CHAPEL HILL, N.C. -- AIDS investigators at the University of North Carolina at Chapel Hill are testing the first of a new class of drugs that attacks HIV before it enters the cell and may prove effective for patients with drug-resistant HIV.

The fusion inhibitor, known as T-20, prevents HIV from fusing with the cell surface membrane. Thus, T-20 attacks HIV in an entirely different way than the most potent HIV agents now in use.

"HIV resistant to the currently available medications would not be expected to be resistant to this drug because of its unique action," says Dr. Joseph Eron, associate professor of medicine at the UNC-CH School of Medicine.

On Feb. 4, Eron will present detailed findings of the study at the Sixth Conference on Retroviruses and Opportunistic Infections in Chicago.

Eron is a principal investigator for this multi-center study begun in August and sponsored by Durham-based Trimeris, Inc., maker of T-20. He says the results are impressive, "particularly when one considers the population that enrolled in this clinical trial is extremely difficult to treat."

The infectious disease specialist notes that the average number of anti-HIV medications taken by the 78 HIV-infected patients prior to the Trimeris Phase II Clinical Trial was nine. None of the agents, including an average of three protease inhibitors per patient, had proven effective in these patients over the long-term. Additionally daunting was the patients' very high average baseline viral load -- the concentration of HIV particles per milliliter of blood. But according to Eron, patients in the new trial taking higher T-20 doses showed up to 90 percent reductions in viral load without major side effects.

In the trial, T-20 was given for 28 days either by continuous subcutaneous infusion or simply by injecting it subcutaneously (much like insulin is administered in diabetes). T-20 was also given either as part of an anti-retroviral drug "cocktail" or as the sole drug.

Eron says the new results definitively show that injection can be an alternative to infusion. Targeted blood levels of T-20 were achieved both through infusion and with twice-daily injections.

"This finding is important because twice-daily injection is far more convenient for patients than a continuous subcutaneous infusion pump," Eron explains.

"I think the study is extremely important because it is a clear demonstration of anti-retroviral effects with an agent that is completely novel, one that works by a different mechanism of action than currently available therapies," Eron says.

Results of this and subsequent T-20 investigations by Trimeris will be aimed at meeting rigorous Food and Drug Administration scrutiny to obtain approval for the drug.

"This particular trial was aimed at finding the correct dose and to show 'proof of principle' that the drug could be administered in a relatively convenient way," Eron says. "The trial lets me and others test a new drug on HIV patients who have failed lots of drugs and provides important information that will allow us to go on and study T-20 in combination with other HIV medications for longer durations."


Story Source:

The above story is based on materials provided by University Of North Carolina At Chapel Hill. Note: Materials may be edited for content and length.


Cite This Page:

University Of North Carolina At Chapel Hill. "UNC Researchers Testing First In New Class Of AIDS Drugs." ScienceDaily. ScienceDaily, 29 January 1999. <www.sciencedaily.com/releases/1999/01/990129074334.htm>.
University Of North Carolina At Chapel Hill. (1999, January 29). UNC Researchers Testing First In New Class Of AIDS Drugs. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/1999/01/990129074334.htm
University Of North Carolina At Chapel Hill. "UNC Researchers Testing First In New Class Of AIDS Drugs." ScienceDaily. www.sciencedaily.com/releases/1999/01/990129074334.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins